• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Exo Therapeutics

  • April 1, 2022
  • New Biotech Startups

Exo Therapeutics leverages its ExoSite™ platform to develop a deep pipeline of potent drug candidates that bind exosites – distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect.

Enzymes play key roles in all metabolic processes, such as destroying toxins and aiding digestion. This critical metabolic role can also make enzymes prime culprits in promoting disease states like cancer or inflammation. One way to treat these diseases is to block or modify enzyme activity, however traditional methods to drug enzymes do not work in many cases. 

Exo has built proprietary capabilities for its application in exosite identification and systematized ligand discovery. The company’s ExoSight™ platform leverages a confluence of recent technologies that enable it to see, model, build, design and discover novel exosite-targeted small molecule drugs. Traditional methods of drug discovery have engaged ~7% of the known target space, but with this proprietary platform, the company has identified exosites in classes of enzymes that represent ~30% of the known target space. Exo’s initial focus is in oncology and inflammation, but will expand its therapeutic horizon as development progresses and through strategic partnerships.

Exo Therapeutics was founded in 2020 by Professor David R. Liu, the Richard Merkin Professor and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT and Alan Saghatelian at the Salk Institute for Biological Studies. It has raised US$78 million in Series B funding on October 5, 2021. 

Subscribe for alerts on new companies featured on Startups.Bio


January 25, 2023MxT Biotech
MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporator™ is a non-viral microfluidic platform …
November 25, 2022Vilya
Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class …
November 16, 2022VentureRadar’s Top 100 Emerging Biotech Start-ups Report
Biotechnology is in the midst of a exciting era of innovation, with an ever-expanding toolbox of modalities and approaches spawning development of exciting new vaccines, medicines and therapies. VentureRadar's Top …
November 2, 2022CorriXR Therapeutics
CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology. CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not …

View all recently featured startups


Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.